PHYSICIANS OFFICE NEWS BRIEFS
Confirmation of these findings in long-term,
called "CIVO." It's specifically designed to test up
to eight drug samples in tumors located near
the surface of the skin, such as skin cancer,
breast cancer, and lymphoma.
The researchers have demonstrated early
success with this device in tests on mice and
dogs, according to their latest study. The
initial human tests were designed to assess
the safety of the device, and to evaluate the
patient and physician experience with the
process, the researchers said. Initial results in
people showed no serious side effects from
the micro-injections of the drugs.
ongoing, pivotal trials with prespecified
primary cardiovascular disease end points
and monitoring of a broad range of adverse
events will help establish the role of these
novel agents in cardiovascular disease risk
management."
T
wo Novel Technologies
Promising in Cancer Care
Two new
devices
may eventually lead
to more accurate, less
toxic methods of
predicting how well a
specific cancer drug
might work on an
individual's cancer,
researchers report.
Findings from both
studies were
published in the April 22 issue of Science
Translational Medicine.
The authors of one study designed a 3mm long device outfitted with isolated
pockets. Each pocket was loaded with very
small sample of a cancer drug. Currently,
16 different cancer drugs can be tested at
once, according to the study. The device
was injected directly into melanoma,
prostate, or breast cancer tumors in a
group of mice. Tissue samples were then
tested to see how the tumor reacted to the
drugs. Those samples were then compared
to how the mice reacted when given a
drug's full dosage. The device proved to be
a reliable and accurate way to predict each
drug's effectiveness.
A second device has been tested on four
humans, but only in a safety trial. This device -from researchers at the Fred Hutchinson Cancer
Research Center and Presage Biosciences in
Seattle -- is a handheld microinjection device
H
igh-Dose Oral Insulin
Promising for Prevention of
T1DM
In a small, preliminary study,
high-dose insulin capsules safely induced
what appears to be a protective immune
response in children at high risk of developing
type 1 diabetes. The study findings were
published in the April 21 issue of the Journal
of the American Medical Association, a theme
issue on child health.
For the study, the researchers recruited 25
children aged 2 to 7 years. All had a strong
family history of type 1 diabetes and were
considered genetically at risk for its
development.
However, the
children had no
signs of islet
autoimmunity.
Fifteen children
were given daily
insulin capsules at
varying doses for
three to 18
months. Ten
children received
inactive placebo
capsules.
Nearly all -- 83.3 percent -- who received
29
www.PhysiciansOfficeResource.com